PDE3A and leukemia: We provide evidence that even in less sensitive leukemia cell lines, BAY 2666605 remains effective at relatively low doses and enhances Aza antileukemic effects, suggesting that this combinatorial strategy could be particularly beneficial for patients with lower PDE3A and higher PDE3B expression.